



## Female infertility: which role for obesity?

Alessandra Gambineri<sup>1</sup> · Daniela Laudisio<sup>2</sup> · Chiara Marocco<sup>3</sup> · Stefano Radellini<sup>4</sup> · Annamaria Colao<sup>2</sup> · Silvia Savastano<sup>2</sup> · on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group

Published online: 12 April 2019

© The Author(s), under exclusive licence to Springer Nature Limited 2019

### Abstract

Obesity is associated with infertility in women through multiple and complex mechanisms. Briefly, the adipose tissue through the production of many factors, such as leptin, free fatty acids (FFA), and cytokines may affect both ovarian and endometrium functions, with a final alteration in oocyte maturation and endometrial epithelium receptivity. In addition, through the development of peripheral insulin resistance obesity produces a condition of functional hyperandrogenism and hyperestrogenism that contribute to produce anovulation and to reduce endometrial receptivity and, therefore participate to cause infertility. Weight loss is able to restore fertility in most cases, but there are no practical indications to guide the clinician to choice the best method among increased physical activity, diet, drugs, and bariatric surgery.

### Introduction

Obesity is associated with a magnitude of complications. These include metabolic complications, cardiovascular events, tumors, gastrointestinal disorders, arthritis, and infertility [1]. The association between obesity and infertility in women is the topic of this review. In particular, the ovarian and extra-ovarian mechanisms at the basis of infertility in obese women are the subject of this review. In addition, the link between obesity and polycystic ovary syndrome (PCOS), the most frequent cause of anovulatory

infertility, will be described, as well as the negative impact of obesity on assisted conception and pregnancy outcomes. Finally, the beneficial effect of weight loss in obese infertile women will be summarized.

### Obesity and the hypothalamic-pituitary-ovarian axis

Body fat in women impacts the function of the hypothalamus-pituitary-ovarian (HPO) axis through central and peripheral mechanisms [2, 3]. Accordingly, clinical studies demonstrate that excessive leanness is associated with puberty delay, whereas obesity is accompanied by premature puberty [4]. These observations have led several researchers to investigate the metabolic mediators and pathways that directly or indirectly interact with the HPO axis in puberty and fertility. The role of adipocytokines, particularly leptin, has been widely studied. Several pieces of evidence from cellular and animal models have shown leptin to be an essential gate-keeper of puberty and future fertility through its stimulatory action on gonadotropin-releasing hormone (GnRH) pulses [5, 6]. Peripheral levels of leptin are directly related to the amount of body fat. Therefore, conditions of defect of body weight cause a decrease in leptin levels that per se suppresses fertility, whereas conditions of excess of body weight are associated with increased leptin secretion. However, most forms of obesity are characterized by a condition of leptin resistance,

---

Members of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group are listed below Acknowledgements.

✉ Alessandra Gambineri  
alessandra.gambiner3@unibo.it

<sup>1</sup> Endocrinology Unit, Department of Medical and Surgical Sciences, Centre for Applied Biomedical Research (C.R.B.A.), S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

<sup>2</sup> Endocrinology Unit, Department of Medical and Surgical Sciences, Federico II University Medical School of Naples, Naples, Italy

<sup>3</sup> Department of Movement, Human and Health Sciences, University of Rome 'Foro Italico', Rome, Italy

<sup>4</sup> Endocrinology and Metabolic Diseases Unit, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), University of Palermo, Palermo, Italy

at least at the central level [7], probably via a down-regulation of leptin receptor expression [8]. Accordingly, Tortoriello et al. observed that mice with higher expression of leptin receptors in the hypothalamus were resistant in developing obesity and infertility [9]. Contrary to the brain, other tissues, such as the ovaries, remain sensitive to leptin, therefore being exposed to the high circulating leptin levels that accompany obesity. Leptin in the human ovary inhibits both granulosa and thecal cell steroidogenesis [10] and interferes with the process of ovulation [11], therefore directly impacting fertility. Finally, a central insulin resistance state that accompanies obesity could be involved in the processes of infertility observed in obesity through the impact on the frequency and amplitude of luteinizing hormone (LH) secretion pulses [12–14].

### Obesity and sex steroids

Several alterations of sex steroids follow the increase in body weight. In particular, obesity is associated with an increase in both estrogens (17 $\beta$ -estradiol-E2 and estrone-E1) and androgens (testosterone-T, dihydrotestosterone-DHT, androstenedione, and dehydroepiandrosterone), because adipose tissue directly synthesizes androgens and converts androgens to estrogens [15]. In addition, obesity is associated with a decrease in sex hormone binding globulin (SHBG) circulating levels [16], with a consequent increased availability of androgens and estrogens to target tissues. These relationships are evident already across puberty [17] and are particularly pronounced in central obesity [18, 19]. In addition, adipose tissue is able to store androgens and estrogens leading to an inflated steroid pool in women with obesity [18, 20].

Overall, these phenomena lead to a condition of “relative functional hyperandrogenism” that may affect ovarian function therefore contributing to the development of infertility in obesity.

### Obesity and insulin

Obesity, especially central obesity, is characterized by a condition of insulin resistance and “compensatory hyperinsulinemia” due to many factors such as free fatty acids (FFA), leptin, cytokines, and androgens [21]. This insulin resistance state interests many tissues, but not all. In particular, muscle, liver, and adipose tissue become resistant to insulin, whereas the ovaries remain sensible to insulin and, therefore, are exposed to the burden effect of hyperinsulinemia. In the ovaries, insulin stimulates theca cells to produce androgens both through a direct effect and by increasing the local sensitivity to LH [22]. The excess of

intra-ovarian androgen production may produce premature follicular atresia thus favoring anovulation [22]. In addition, hyperinsulinemia leads to reduced hepatic synthesis of SHBG with a consequent increased availability of free androgens [23], thus aggravating peripheral hyperandrogenism that triggers an overproduction of acyclic E1 which, in turn, determines an excessive production of LH [24]. Increased secretion of LH may arrest follicular growth at earlier stages, may promote early luteinization of granulosa cells and may produce a damage of oocyte quality [25–30]. Through all these mechanisms, insulin resistance and compensatory hyperinsulinemia may contribute to menstrual, ovulatory, and fertility disturbances that accompany obesity, particularly central obesity, in women.

### Obesity and the somatotrophic axis

Obese patients are characterized by a decrease of plasma GH levels due to a reduction of GH secretion and an increased GH clearance rate [31–33]. Many factors participate in reducing plasma GH levels, in particular dysregulation of GH-releasing hormone (GHRH), somatostatin (SS), and ghrelin pathways, as well as hyperinsulinemia and excess of circulating FFA [34]. Data on circulating IGF-1 levels in obesity are contradictory. In fact, several clinical studies showed that in people with obesity total IGF-1 are unaltered, but other studies demonstrated increased levels of IGF-1 [35] and of free IGF-1 for the insulin dependent reduction in IGF Binding Protein (IGFBP)-1 and IGFBP-2 levels [36], which could be responsible for an enhanced feedback inhibition of GH release [35]. These findings provide evidence that obesity is characterized by a condition of hyposomatotropinism [37] that could contribute to affect ovarian and endometrial functions, therefore participating to the fertility alterations that accompany obesity. In fact, GH stimulates growth of small follicles and prevents their atresia, collaborates with gonadotrophins in stimulating later stages of folliculogenesis and luteinization, and facilitates selection and development of dominant follicle. In addition, GH increases the ovarian production of oestrogens and progesterone and stimulates endometrium and myometrium in the uterus, all mechanisms that are a prerequisite for successful reproduction [38].

### Obesity and the ovary

Sex steroids, insulin, and the somatotrophic axis act at the level of the ovary [38]. Therefore, the dysfunctions that affect these systems when body weight increases may be involved in producing functional alterations in the ovary. However, there is emerging evidence that obesity may

directly impact the oocyte, impairing its quality. Animal studies have, in fact, demonstrated that oocytes from obese mice are smaller, show delayed meiotic maturation and increased follicular apoptosis and have significant spindle or chromosome misalignment defects [39, 40]. These defects are likely to generate embryos with massive aneuploidy, therefore cause of spontaneous miscarriages. Similar results were obtained in human studies where the comparison of failed fertilized oocytes from patients with severe obesity or who were normal-weight demonstrated that women with obesity have a significantly higher prevalence of “disarrayed meiotic spindles with non-aligned chromosomes” [41]. One proposed mechanism at the basis of the altered oocyte quality in women with obesity includes altered mitochondrial activity. In fact, mitochondria perform numerous regulatory functions during oocyte maturation, fertilization, preimplantation, and normal embryo development [42–44]. Furthermore, mitochondria from obese female mice present an aberrant distribution within the oocyte [45] and are more oxidized with a rate of Reactive Oxygen Species (ROS) production 2.1-fold higher with respect to lean controls and with depleted levels of glutathione [45]. Accordingly, the mitochondrial DNA copy number is significantly higher in oocytes from obese mice with respect to lean controls [45], probably as compensatory mechanism in response to oxidative-stress-induced mitochondrial damage [40].

Also the lipotoxicity may directly alter the oocyte quality, thus contributing to infertility in obese women [46–48]. In particular, both animal and human studies demonstrate that the accumulation of FFA within the ovary is associated with endoplasmic reticulum (ER) stress, mitochondrial dysfunction of the oocytes, and finally apoptosis of the cumulus–oocyte complexes [49, 50]. These data provide new informations about the mechanisms that may lead to impaired ovulation, reduced oocyte and embryo quality, and therefore to infertility in women with obesity.

## Obesity and the endometrium

The endometrium is another target of obesity. Studies of mice with diet-induced obesity demonstrated that endometrial decidualization is impaired [51]. These results were confirmed in *in vitro* and *in vivo* human studies, where a decreased stromal decidualization was observed in women with obesity [52]. The pathogenesis of this phenomenon may lie on proinflammatory cytokines and ROS inducing endothelial dysfunction [53] and on haptoglobin, an inflammatory marker whose endometrial levels of expression have been found to be increased in women with obesity who had recurrent miscarriages [54]. In addition, in a recent study, the ERK signal transduction, which belongs to

MAPK/ERK pathways, necessary for invasion of trophoblasts into the endometrium, was found to be down-regulated during implantation in women with obesity [55]. All these phenomena represent possible mechanisms of decreased implantation and high miscarriage rates in women with obesity. It has also been suggested a condition of reduced endometrial receptivity in obesity due to many factors, in particular the relative hyperestrogenemia, the reduction of glycodelin and of IGFBP1 that follow insulin resistance and hyperinsulinemia, and the dysregulation of leptin pathways [56–58]. Leptin, other than modulating endometrial receptivity, exerts a regulatory role in remodeling the endometrial epithelium and in stimulating proliferation and apoptotic cell pathways [58]. All these data support the notion that infertility in obesity is sustained by an unfavorable intrauterine milieu and impaired endometrial receptivity, other than by an altered oocyte quality.

## Obesity and assisted conception

Several clinical studies have focused on the impact of female obesity on the outcome of assisted reproduction technology (ART). Up to date, although some studies have not reported adverse effect of obesity on ART outcomes [59–63], most studies have linked obesity with negative ART outcomes. In particular, obesity is associated with the need for higher doses of gonadotropins, fewer oocytes collected, higher number of cycles canceled for poor or high oocytes retrieved (overstimulation), higher miscarriage rates and reduced pregnancy and live-birth rates [64–66]. Moreover, a specific meta-analysis made by Rittenberg et al. that included 33 studies for a total of 47,967 IVF/ICSI cycles interestingly demonstrated that the poorer outcome of IVF treatment was not limited to women with obesity, but included also women with overweight [67].

The elevated doses of gonadotropins used to compensate for the relative gonadotropin resistance induced by obesity may be deleterious for fertility, leading to impairment of uterine receptivity and of embryonic development and implantation [68–70].

In summary, it is widely accepted that overweight and obesity negatively impact the ART outcomes in women. Accordingly, it has been observed that a reduction in body weight is able to improve IVF treatment success in term of number of oocytes retrieved, number of mature oocytes developed and pregnancy rate [71, 72].

## Obesity and pregnancy outcome

Maternal obesity increases the risk of complications in pregnancy, labor, and birth for both the mother and the

neonate. In fact, maternal obesity is associated with increased rates of pregnancy complications, mainly in the third trimester [73, 74], as well as increased rates of fetal malformations [75, 76] and increased risk of intrauterine fetal death and of death of the neonate in the first year of life [73, 77]. In addition, neonates of mothers with obesity have increased rates of neonatal complications such as head trauma, shoulder dystocia, brachial plexus lesions, fractures of the clavicle, meconium aspiration, and respiratory distress [73, 77].

## Fertility after weight loss

Many interventions have been studied to reduce the effect of obesity on infertility, including weight loss, dietary factors, physical activity and bariatric surgery but, to date, there are still no precise indications on how to solve the problem in the most effective way. Clark and colleagues [78] showed that weight loss in obese infertile women is extremely effective for the resumption of ovulation, improvement of spontaneous pregnancy rate, and reduction of miscarriage rate. The amount of weight loss required for the resumption of fertility is however unclear. Sim and colleagues recently demonstrated that a loss of only 6.9% of initial body weight is sufficient to enhance pregnancy rates [79]. In women with massive obesity, bariatric surgery has been shown to improve fertility, but to date there is no consensus on the role of bariatric surgery in the management of infertility-associated obesity within the medical community. Musella and coworkers described a 78.5% of pregnancies in obese infertile women after weight loss induced by Bioenterics Intra-gastric Balloon (BIB) treatment [80]. The beneficial effect of bariatric surgery on anovulatory infertility was demonstrated in a survey study of 195 anovulatory obese women who regained ovulation in 71% of cases after surgery [81]. However, a recently performed pilot study demonstrated that a brief intensive weight loss intervention in subfertile women with severe obesity resulted in improvement in ovulation similarly to bariatric surgery [82]. More studies are warranted to corroborate these interesting results.

## Obesity and polycystic ovary syndrome


Polycystic ovary syndrome (PCOS) is one of the most common causes of anovulatory infertility in women. Obesity, that affects approximately half of PCOS women [83], aggravates infertility through the negative impact on menses, ovulation, as well as pregnancy and live birth rates [84, 85]. Moreover, a blunted responsiveness to pharmacological treatments to induce ovulation, as well as higher gonadotropin requirements during ART stimulation with, however, fewer oocytes recruited, have been described in

obese with respect to non-obese PCOS [86, 87]. Pathophysiological mechanisms by which obesity negatively impacts fertility in PCOS are complex and not completely understood. Undoubtedly, obesity aggravates hyperandrogenism and insulin resistance, and is associated with hypsomatotropinism in PCOS, particularly in abdominal obesity [19, 88, 89]. The important impact of obesity in aggravating infertility in PCOS is supported by the studies that demonstrate that lifestyle interventions, including dietary advice and standardized physical activity programs, have a significant positive impact on ovulation, menses abnormalities and infertility [90, 91], and these beneficial effects have been observed even after modest weight loss of 5–10% [92–94]. Studies on the effects of bariatric surgery in women with severe obesity and PCOS reported interesting data on the benefits of sustained weight loss on fertility. In particular, a recent meta-analysis [95] demonstrated that after 1 year from bariatric surgery in women with severe obesity and PCOS, the prevalence of menstrual irregularities decreased from 56.2 to 7.7% and the prevalence of infertility declined from 18.2 to 4.3%.

## Conclusion

In conclusion, obesity is associated with infertility in women through multiple and complex mechanisms that are summarized in Fig. 1. Briefly, obesity is associated with high serum leptin levels due to leptin produced by the adipose tissue. Leptin acts at the level of the ovary and of the endometrium where it inhibits both human granulosa and thecal cell steroidogenesis, which interferes with the development of the dominant follicle and oocyte maturation, and alters endometrial epithelium receptivity. High leptin levels may also contribute to the development of peripheral insulin resistance. On the other hand, the condition of selective leptin resistance at central level that accompanies obesity reduces stimulation of GnRH. Obesity, particularly the abdominal phenotype, is also associated with an increase in E2, E1 and in some androgens, such as T, DHT, androstenedione, and dehydroepiandrosterone for an increased synthesis and storage at the level of the adipose tissue, and with a parallel decrease in SHBG circulating levels, with a consequent increased delivery of androgens and estrogens to target tissues. The exposure of the ovary at high androgen levels produces premature follicular atresia, thus contributing to anovulation. On the other hand, hyperestrogenemia may have a detrimental effect upon endometrial receptivity, thus contributing to infertility. Hyperandrogenemia, hyperleptinemia, but also high FFA and cytokines such as Interleukin-6 (IL6) and Tumor Necrosis Factor- $\alpha$  (TNF $\alpha$ ) contribute to induce a state of insulin resistance, that interestingly affects classic target tissues of insulin action (i.e., muscle, liver and adipose

**Fig. 1** Mechanisms linking obesity with infertility. TNF- $\alpha$  tumor necrosis factor- $\alpha$ , IL-6 interleukin-6, FFA free fatty acid, GH growth hormone, SHBG sex hormone binding globulin, IGF BPs insulin-like growth factor-binding proteins



tissue), but not the ovaries. The ovary, under the effect of hyperinsulinemia that compensates insulin resistance, synthesizes more androgens, particularly A and T that cause premature follicular atresia. Hyperinsulinemia and excess of circulating FFA, in association with a dysregulation of GHRH, SS, and ghrelin pathways contribute to determine the low GH status that accompanies obesity and that could contribute to affect ovarian and endometrial functions. Accumulation of FFA within the ovary is also associated with ER stress, mitochondrial dysfunction of the oocytes, and apoptosis of the cumulus–oocyte complexes, with a consequent delayed meiotic maturation, increased aneuploidia and follicular apoptosis. In addition, high FFA and cytokines and a reduction of glycodelin and of IGFBP1 that follow insulin resistance and hyperinsulinemia interfere with endometrial decidualization, the necessary step for uterine receptivity.

Weight loss is able to restore fertility in most cases. However, nowadays, there are no convincing studies to guide the choice of the best method to be used to induce weight loss among physical activity, diet and bariatric surgery and to tailoring therapy.

**Acknowledgements** Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group members served as collaborators and approved the final version of the manuscript: Annamaria Colao, Antonio Aversa, Barbara Altieri, Luigi Angrisani, Giuseppe Annunziata, Rocco Barazzoni, Luigi Barrea, Giuseppe Bellastella, Bernadette Biondi, Elena Cantone, Brunella Capaldo, Sara Cassarano, Rosario Cuomo, Luigi Di Luigi, Andrea Di Nisio, Carla Di Somma, Ludovico Docimo, Katherine Esposito, Carlo Foresta, Pietro Forestieri, Alessandra Gambineri, Francesco Garifalos, Cristiano Giardiello, Carla Giordano, Francesco Giorgino, Dario Giugliano, Daniela

Laudisio, Davide Lauro, Andrea Lenzi, Silvia Magno, Paolo Macchia, MariaIda Maiorino, Emilio Manno, Chiara Marocco, Paolo Marzullo, Chiara Mele, Davide Menafra, Silvia Migliaccio, Marcello Monda, Filomena Morisco, Fabrizio Muratori, Giovanna Muscogiuri, Mario Musella, Gerardo Nardone, Claudia Oriolo, Uberto Pagotto, Pasquale Perrone Filardi, Luigi Piazza, Rosario Pivonello, Barbara Polese, Paolo Pozzilli, Giulia Puliani, Stefano Radellini, Gabriele Riccardi, Domenico Salvatore, Ferruccio Santini, Giovanni Sarnelli, Lorenzo Scappaticcio, Silvia Savastano, Bruno Trimarco, Dario Tuccinardi, Paola Vairano, Nunzia Verde, Roberto Vettor.

**Funding** This article is published as part of a supplement funded by Endocrinology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

**Author contributions** The author's responsibilities were as follows: AG, DL, CM, and SR were responsible for the concept of this paper and drafted the manuscript; AG, SS, and AC provided a critical review of the paper.

### Compliance with ethical standards

**Conflict of interest** AG is a consultant for Bayer. The remaining authors declare that they have no conflict of interest.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### References

1. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. *Hum Reprod Update*. 2003;9:359–72.
2. Michalakis K, Mintzioti G, Kaprara A, Tarlatzis BC, Goulis DG. The complex interaction between obesity, metabolic syndrome



- and reproductive axis: a narrative review. *Metabolism*. 2013;62:457–78.
3. Evans JJ, Anderson GM. Balancing ovulation and anovulation: integration of the reproductive and energy balance axes by neuropeptides. *Hum Reprod Update*. 2012;18:313–32.
  4. Castellano JM, Bentsen AH, Sánchez-Garrido MA, Ruiz-Pino F, Romero M, Garcia-Galiano D, et al. Early metabolic programming of puberty onset: impact of changes in postnatal feeding and rearing conditions on the timing of puberty and development of the hypothalamic kisspeptin system. *Endocrinology*. 2011;152:3396–408.
  5. Quenell JH, Mulligan AC, Tups A, Liu X, Phipps SJ, Kemp CJ, et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. *Endocrinology*. 2009;150:2805–12.
  6. Quenell JH, Howell CS, Roa J, Augustine RA, Grattan DR, Anderson GM. Leptin deficiency and diet-induced obesity reduce hypothalamic kisspeptin expression in mice. *Endocrinology*. 2011;152:1541–50.
  7. Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: a review. *Fertil Steril*. 2002;77:433–44.
  8. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. *Fertil Steril*. 2017;107:840–7.
  9. Tortoriello DV, McMinn JE, Chua SC. Increased expression of hypothalamic leptin receptor and adiponectin accompany resistance to dietary-induced obesity and infertility in female C57BL/6J mice. *Int J Obes*. 2007;31:395–402.
  10. Agarwal SK, Vogel K, Weitsman SR, Magoffin DA. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. *J Clin Endocrinol Metab*. 1999;84:1072–6.
  11. Duggal PS, Van Der Hoek KH, Milner CR, Ryan NK, Armstrong DT, Magoffin DA, et al. The in vivo and in vitro effects of exogenous leptin on ovulation in the rat. *Endocrinology*. 2000;141:1971–6.
  12. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. Role of brain insulin receptor in control of body weight and reproduction. *Science*. 2000;289:2122–5.
  13. van Leckwyck M, Kong W, Burton KJ, Amati F, Vionnet N, Pralong FP. Decreasing insulin sensitivity in women induces alterations in LH pulsatility. *J Clin Endocrinol Metab*. 2016;101:3240–9.
  14. Jain A, Polotsky AJ, Rochester D, Berga SL, Loucks T, Zeitlian G, et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. *J Clin Endocrinol Metab*. 2007;92:2468–73.
  15. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17 $\beta$ -hydroxysteroid dehydrogenase type 5. *J Endocrinol*. 2004;183:331–42.
  16. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. *J Clin Endocrinol Metab*. 2005;90:4836–45.
  17. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. *J Clin Endocrinol Metab*. 2007;92:430–6.
  18. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. *Int J Obes Relat Metab Disord*. 2002;26:883–96.
  19. Norman RJ, Clark AM. Obesity and reproductive disorders: a review. *Reprod Fertil Dev*. 1998;10:55–63.
  20. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. *Reprod Biomed Online*. 2006;12:542–51.
  21. Matthaie S, Stumvoll M, Kellerer M, Häring HU. Pathophysiology and pharmacological treatment of insulin resistance. *Endocr Rev*. 2000;21:585–618.
  22. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. *Endocr Rev*. 1999;20:535–82.
  23. Toprak S, Yönel A, Cakir B, Güler S, Azal O, Ozata M, et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. *Horm Res*. 2001;55:65–70.
  24. Höjlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. *Dan Med J*. 2014;61:B4890.
  25. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. *Reprod Biol Endocrinol*. 2016;14:38.
  26. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Polycystic ovarian syndrome: an updated overview. *Front Physiol*. 2016;7:124.
  27. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. *Am J Physiol Endocrinol Metab*. 2009;296:E238–43.
  28. Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. *Reprod Biol Endocrinol*. 2012;10:36.
  29. Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. *Reprod Biol*. 2016;16:53–60.
  30. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. *Hum Reprod Update*. 2011;17:17–33.
  31. Slowinska-Szrednicka J, Zgliczynski W, Makowska A, Jeske W, Brezinska A, Saszynski P, et al. An abnormality of the growth hormone=insulin-like growth factor-1 axis in women with polycystic ovary syndrome due to coexistent obesity. *J Clin Endocrinol Metab*. 1992;74:1432–5.
  32. Veldhuis JD, Iranmanesh A, Ho KKY, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropinism of obesity in man. *J Clin Endocrinol Metab*. 1991;72:51–59.
  33. Beryman DE, Gla CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. *Nat Rev Endocrinol*. 2013;9:346–56.
  34. Vijayakumar A, Yakar S, LeRoith D. The intricate role of growth hormone in metabolism. *Front Endocrinol*. 2011;2:1–11.
  35. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. *Growth Hormon. IGF Res*. 2003;13:113–70.
  36. Frystyk J, Brick DJ, Gerweck AV, Utz AL, Miller LL. Bioactive insulin-like growth factor- I in obesity. *J Clin Endocrinol Metab*. 2009;94:3093–7.
  37. Savastano S, Di Somma C, Barrea L, Colao A. The complex relationship between obesity and the somatotropic axis: the long and winding road. *Growth Horm IGF Res*. 2014;24:221–6.
  38. Hull KL, Harvey S. Growth hormone: roles in female reproduction. *J Endocrinol*. 2001;168:1–23.
  39. Jungheim ES, Schoeller EL, Marquard KL, Loudon ED, Schaffer JE, Moley KH. Diet-induced obesity model: abnormal oocytes and persistent growth abnormalities in the offspring. *Endocrinology*. 2010;151:4039–46.
  40. Luzzo KM, Wang Q, Purcell SH, Chi M, Jimenez PT, Grindler N, et al. High fat diet induced developmental defects in the mouse: oocyte meiotic aneuploidy and fetal growth retardation/brain defects. *PLoS ONE*. 2012;7:e49217.

41. Machtinger R, Combelles CMH, Missmer SA, Correia KF, Fox JH, Racowsky C. The association between severe obesity and characteristics of failed fertilized oocytes. *Human Reproduction*. 2012;27:3198–207.
42. Cummins JM. The role of mitochondria in the establishment of oocyte functional competence. *Eur J Obstet Gynecol Reprod Biol*. 2004;115:S23–S29.
43. Dumollard R, Duchen M, Carroll J. The role of mitochondrial function in the oocyte and embryo. *Curr Top Dev Biol*. 2007;77:21–49.
44. Torner H, Brüßow KP, Alm H, Ratky J, Pöhland R, Tuchscherer A, et al. Mitochondrial aggregation patterns and activity in porcine oocytes and apoptosis in surrounding cumulus cells depends on the stage of pre-ovulatory maturation. *Theriogenology*. 2004;61:1675–89.
45. Igosheva N, Abramov AY, Poston L, Eckert JJ, Fleming TP, Duchen MR, et al. Maternal diet-induced obesity alters mitochondrial activity and redox status in mouse oocytes and zygotes. *PLoS ONE*. 2010;5:e10074.
46. Wu LL, Dunning KR, Yang X, Russell DL, Lane M, Norman RJ, et al. High-fat diet causes lipotoxicity responses in cumulus-oocyte complexes and decreased fertilization rates. *Endocrinology*. 2010;151:5438–45.
47. Jungheim ES, Travieso JL, Carson KR, Moley KH. Obesity and reproductive function. *Obstet Gynecology Clin North Am*. 2012;39:479–93.
48. Wu LL, Norman RJ, Robker RL. The impact of obesity on oocytes: evidence for lipotoxicity mechanisms. *Reprod Fertil Dev*. 2011;24:29–34.
49. Broughton DE, Jungheim ES. A focused look at obesity and the preimplantation trophoblast. *Semin Reprod Med*. 2016;34:5–10.
50. Jungheim ES, Macones GA, Odem RR, Patterson BW, Lanzendorf SE, Ratts VS, et al. Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization. *Fertil Steril*. 2011;95:1970–4.
51. Rhee JS, Saben JL, Mayer AL, Schulte MB, Asghar Z, Stephens C, et al. Diet-induced obesity impairs endometrial stromal cell decidualization: a potential role for impaired autophagy. *Hum Reprod*. 2016;31:1315–26.
52. Hill MJ, Uyehara CFT, Hashiro GM, Frattarelli JL. The utility of serum leptin and follicular fluid leptin, estradiol and progesterone levels during an in vitro fertilization cycle. *J Assist Reprod Genet*. 2007;24:183–8.
53. Palomba S, de Wilde M, Falbo A, Koster MPH, La Sala GB, and Fauseet BCJM. Pregnancy complications in women with polycystic ovary syndrome. *Human Reprod Update*. 2015; 21:575–92.
54. Metwally M, Preece R, Thomas J, Ledger W, Chiu LiT. A proteomic analysis of the endometrium in obese and overweight women with recurrent miscarriage: preliminary evidence for an endometrial defect. *Reprod Biol Endocrinol*. 2014;12:75.
55. Qiu Q, Yang M, Tsang BK, Gruslin A. Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration. *Mol Human Reprod*. 2004;10:677–84.
56. Tamer Erel C, Senturk LM. The impact of body mass index on assisted reproduction. *Curr Opin Obstet Gynecol*. 2009;21:228–35.
57. Carrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. *Curr Opin Obstet Gynecol*. 2005;17:591–7.
58. Tanaka T, Umesaki N. Leptin regulates the proliferation and apoptosis of human endometrial epithelial cells. *Int J Mol Med*. 2008;22:683–9.
59. Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. *Hum Reprod*. 2002;17:3220–3.
60. Styne-Gross A, Elkind-Hirsch K, Scott RT Jr. Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation. *Fertil Steril*. 2005;83:1629–34.
61. Dechaud H, Anahory T, Reyftmann L, Loup V, Hamamah S, Hedon B. Obesity does not adversely affect results in patients who are undergoing in vitro fertilization and embryo transfer. *Eur J Obstet Gynecol Reprod Biol*. 2006;127:88–93.
62. Matalliotakis I, Cakmak H, Sakkas D, Mahutte N, Koumantakis G, Arici A. Impact of body mass index on IVF and ICSI outcome: a retrospective study. *Reprod Biomed Online*. 2008;16:778–83.
63. Banker M, Sorathiya D, Shah S. Effect of body mass index on the outcome of in-vitro fertilization/intracytoplasmic sperm injection in women. *J Hum Repro Sci*. 2017;10:37–43.
64. Kumbak B, Oral E, Bukulmez O. Female obesity and assisted reproductive technologies. *Semin Reprod Med*. 2012;3:507–16.
65. Luke B, Brown MB, Stern JE, Missmer SA, Fujimoto VY, Leach R, SART Writing Group. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. *Hum Reprod*. 2011;26:245–52.
66. Luke B, Brown MB, Missmer SA, Bukulmez O, Leach R, Stern JE, et al. The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study. *Hum Reprod*. 2011;96:820–5.
67. Rittenberg V, Seshadri S, Sunkara SK, Sobaleva S, Oteng-Ntim E, El-Toukhy T. Effect of body mass index on IVF treatment outcome: an updated systematic review and meta-analysis. *Reprod Biomed Online*. 2011;23:421–39.
68. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. *Human Reprod*. 2001;16:1086–91.
69. Ertzeid G, Storeng R. Adverse effects of gonadotropin treatment on pre- and postimplantation development in mice. *J Reprod Fertility*. 1992;96:649–55.
70. Ertzeid G, Storeng R, Lyberg T. Treatment with gonadotropins impaired implantation and fetal development in mice. *J Assist Reprod Genet*. 1993;10:286–91.
71. Becker GF, Passos EP, Moulin CC. Short-term effects of a hypocaloric diet with low glycemic index and low glycemic load on body adiposity, metabolic variables, ghrelin, leptin, and pregnancy rate in overweight and obese infertile women: a randomized controlled trial. *Am J Clin Nutr*. 2015;102:1365–72.
72. Sim KA, Dezarnaulds GM, Denyer GS, Skilton MR, Caterson ID. Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: a randomized controlled trial. *Clin Obes*. 2014;4:61–8.
73. Public Affairs Committee of the Teratology Society. Teratology Public Affairs Committee position paper: maternal obesity and pregnancy. *Birth Defect Res*. 2006;76:73–7.
74. Kabiru W, Raynor D. Obstetric outcome associated with increase in BMI category during pregnancy. *Am J Obstet Gynaecol*. 2004;191:928–32.
75. Linne Y. Effects of obesity on women's reproduction and complications during pregnancy. *Obes Rev*. 2004;5:137–43.
76. Hall F, Neubert A. Obesity and pregnancy. *Obstet Gynaecol Sur*. 2005;4:253J–60J.
77. Kabiru W, Raynor D. Obstetric outcome associated with increase in BMI category during pregnancy. *Am J Obstet Gynaecol*. 2004;191:928–32.
78. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. *Human Reprod*. 1998;13:1502–5.
79. Sim KA, Dezarnaulds GM, Denyer GS, Skilton MR, Caterson ID. Weight loss improves reproductive outcomes in obese women

- undergoing fertility treatment: a randomized controlled trial. *Clin Obes.* 2014;4:61–8.
80. Musella M, Milone M, Bellini M, Sosa Fernandez ME, Sosa Fernandez LM, Leongito M, et al. The potential role of intra-gastric balloon in the treatment of obese-related infertility: personal experience. *Obes Surg.* 2011;21:426–30.
  81. Teitelman M, Grotgut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. *Obes Surg.* 2006;16:1457–63.
  82. Rothberg A, Lanham M, Randolph J, Fowler C, Miller N, Smith Y. The feasibility of a brief, intensive weight loss intervention to improve reproductive outcomes in obese, subfertile women: a pilot study. *Fertil Steril.* 2016;106:1212–20.
  83. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med.* 2005;352:1223–36.
  84. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. *Br J Obstet Gynecol.* 2006;113:1148–59.
  85. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. *Human Reproduction.* 1995;10:2107–11.
  86. Pasquali R, Patton L, Gambineri A. Obesity and infertility. *Curr Opin Endocrinol Diabetes Obes.* 2007;14:482–7.
  87. Jungheim ES, Lanzendorf SE, Odem RR, Moley KH, Chang AS, Ratts VS. Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. *Fertil Steril.* 2009;92:256–61.
  88. Pasquali R, Gambineri A. PCOS: a multifaceted disease from adolescence to adult age. *Ann NY Acad Sci.* 2006;1092:158–74.
  89. Barber TM, McCarthy MI, Wass JAH, Franks S. Obesity and polycystic ovary syndrome. *Clin Endocrinol.* 2006; 65:137–45.
  90. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. *Fertil Steril.* 2009;92:966–82.
  91. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev.* 2011;7:CD007506.
  92. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. *Clin Endocrinol.* 1992;36:105–11.
  93. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. *Human Reprod.* 2003;18:1928–32.
  94. Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. *Eur J Endocrinol.* 2011;164:53–60.
  95. Skubleny D, Switzer NJ, Gill RS, Dykstra M, Shi X, Sagle MA, et al. The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis. *Obes Surg.* 2016;26:169–76.